Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses. Diagnosis of influenza is mainly based on laboratory testing (i.e. molecular testing) of nasopharyngeal samples....

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome: coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). As of December 2023, eight vaccines (Comirnaty, Spikevax, Vaxzevria, Jcovden Valneva, Nuvaxovid, VidPrevtyn, and Bimervax) have been...

This core protocol for ECDC studies of VE against hospitalisation with severe acute respiratory infection (SARI) laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). As of October 2023, almost 276 million cases and more than 2.2 million deaths had been reported in the WHO European Region [1]. As of October...

This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratoryconfirmed influenza or SARS-CoV-2 infection, respectively, at primary care level. This core protocol presents the main elements for a multicentre (multi-country) study of IVE/CVE at primary...

This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still...

Compared with the general public, people in prison in the EU/EEA have a higher burden of communicable diseases such as human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, gonorrhoea, chlamydia and tuberculosis (TB). Increased disease prevalence in this population is...

A higher prevalence of communicable diseases among people in prison compared with the general public is recognised as a public health issue as well as a major concern for the people affected, as the majority of incarcerated people return to their communities. Active case finding is a key...